Ticker Details
Solid Biosciences Inc. Solid Biosciences Inc is a life science company engaged in developing therapies for Duchenne muscular dystrophy. Its product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles.
IPO Date:	January 26, 2018
Sector:	Healthcare
Industry:	Drug Manufacturers
Market Cap:	$1.1B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.35 | 4.37%
Avg Daily Range (30 D):	$0.34 | 4.30%
Avg Daily Range (90 D):	$0.33 | 4.42%

Institutional Daily Volume
Avg Daily Volume:	.4M
Avg Daily Volume (30 D):	1.71M
Avg Daily Volume (90 D):	1.36M

Trade Size
Avg Trade Size (Sh.):	74
Avg Trade Size (Sh.) (30 D):	87
Avg Trade Size (Sh.) (90 D):	84

Institutional Trades
Total Institutional Trades:	566
Avg Institutional Trade:	$1.62M
Avg Institutional Trade (30 D):	$2.9M
Avg Institutional Trade (90 D):	$1.86M
Avg Institutional Trade Volume:	.14M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.95M
Avg Closing Trade (30 D):	$4.36M
Avg Closing Trade (90 D):	$2.08M
Avg Closing Volume:	191.02K

News

May 26, 2026 @ 5:00 PM Duchenne Muscular Dystrophy Clinical Trial Pipelin... Source: Delveinsight

Dec 16, 2025 @ 9:51 PM Solid Biosciences Announces Duchenne Muscular Dyst... Source: Solid Biosciences Inc.

Dec 1, 2025 @ 1:00 PM Solid Biosciences Receives FDA Rare Pediatric Dise... Source: Solid Biosciences Inc.

Nov 17, 2025 @ 1:00 PM Solid Biosciences Announces Licensing Agreement wi... Source: Solid Biosciences Inc.

Nov 11, 2025 @ 1:00 PM Solid Biosciences to Participate at Upcoming Inves... Source: Nicole Anderson

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-1.95	$-.52	$-.53
Diluted EPS	$-1.95	$-.52	$-.53
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-191.78M	$-56.74M	$-49.79M
Operating Income / Loss	$-196.46M	$-57.31M	$-49.4M
Cost of Revenue
Net Cash Flow	$85.84M	$236.56M	$-1.4M
PE Ratio

Splits
Oct 28, 2022	1:15